News Release Medtronic has received a CE Mark and simultaneously launched the Captivia Delivery System internationally for the Valiant thoracic stent graft, a minimally invasive treatment for aneurysms and other lesions of the thoracic aorta.

The Captivia Delivery System features tip capture for enhanced control of the Valiant thoracic stent graft during deployment and a hydrophilic coating applied to the graft cover to facilitate iliac access and delivery through patients’ vasculature, according to the Minneapolis-based company. The Valiant Captivia enables physicians to treat a range of anatomies with a stent graft.

Both the Valiant thoracic stent graft and Captivia Delivery System are investigational in the U.S., where their use is limited to clinical trials approved by the FDA.